hypokalemia. ・Fig1 You should be analyzed in each of the items (age, body weight, YK (full dose, dosing period), co-administration of LPIDs, serum potassium, ALT, AST, ALB, BUN, Cre, etc.) of Table 2 . Each risk factor should be analyzed by univariate logistic regression analysis. Age, albumin etc. should be analyzed by continuous variables and calculated cut-off values. Subsequently, the data should be analyzed using multivariate logistic regression analysis. ・Please write P-values in another column of Table2, 3. ・P9 L8 I wasn't able to understand hypokalemia onset days from figure 2. Please change from "Figure 2" to " Table 2 ". ・P9 L13 I wasn't able to identify "onset time by 15days" from figure 2. Can you do it? Please delete " (Figure 2 )" of P9 L13. ・P9 L17
Why the wet extraction rate of GL is different even if the licorice contents are the same (1.5 g/day) in YK and YKCH? Is there any evidence? Please add references. Table 3 , authors categorized the AST or ALT into normal group or abnormal group. In the abnormal group, is low serum AST or ALT included? 5. In Table 4 , please separate co-medications from symptoms. 6. In Fig. 2 , some patients reached hypokalemia after 1600 days from the start of YK preparations. Even 200 days from start of YK, is it really by YK preparations? If you cut 100 days from the start of YK preparations, the result will be totally different. 
REVIEWER

GENERAL COMMENTS
In this observational study the authors aim to evaluate the rates of hypokalemia in patients treated with licorice-containing Japanese traditional Kampo medicines Yokukansan (YK) and Yokukansan-kachinpihange (YKCH). The authors also evaluate risk factors that could modulate the rates of hypokalemia.
The authors described this observational study as a retrospective case-control study and used a logistic regression model to analyse the data. In my opinion this study design could be analysed as a retrospective cohort study. In fact, it seems that the researchers have information on the time (days) on which the event (hypokalemia) occur or when the treatment was ended. It is not clear if they were able to record the last follow up time.
There will be several advantage if data from this study will be analysed using time-to-event methods like Kaplan-Meier and Cox regression models; some of them are reported below; 1) In the abstract (page 2 line 12) the author claim that the main outcome is to measure the occurrence rate of hypokalemia. A rate by definition need to be referred to a given time period. In fact, it is not clear what time dimension has the estimates (24%) reported in the result section (page 6 line 8). The authors reported 34 days and the range (1-1600) days. Does the 24% estimate refer to the 34 days' period? I recommend to use methods (e.g Kaplan-Meier) that allows to estimate cumulative rates over a specific time period.
2) The logistic model used by the authors could give biased results on analysis time-to event data when the rate is not low and the follow up time increase over time. Moreover, the Odds Ratio deviate from the Risk Ratio when the event of interest is not rare. For example, in the discussion section (page 9 line 10) the authors state "Patients co-administered with LPIDs were 3.3 times more likely to develop to hypokalemia than with YK preparation alone", but the risk ratios as measured by the hazard ratios will be lower. I recommend using time-to-event methods (e.g Cox proportional hazard model). In these models each event is compared with controls at the time on which the event occurs.
3) Using time-to-event models is possible to have more information on some aspect of the treatment (e.g cumulative dose). These exposures could be modelled as time-varying covariates. Other points 1) Patient and study design section (page 5 line 18). Non compliant patient were excluded from the study. Could this choice bias the results: e.g. non compliant patient could have a more severe phenotype? 2) Patient and study design section (page 5 line 20). This sentence is not clear to me. Do the authors recorded laboratory data only when they observed a change? How a change was defined? 3) I think that the Odds Ratios presented in figure 1 are mutually adjusted in a multivariable logistic regression model. This procedure should be discussed in more detail in the Statistical method section (page 5 line 1-5).
4) Have the authors considered in the multivariable logistic model to adjust also for the baseline potassium level? 5) To assess the effects of LPID co-administration on occurrence of hypokalemia the authors compared the period of treatment before the occurrence in the groups with and without LPIDs (figure 2). The author claim that a difference was observed (page 7 line 1-2), but not statistical test was performed or at least reported. I would highlight here that this analysis is exactly an example of time-toevent analysis (in fact these are Kaplan-Meier curves), and this analysis can be done for any other risk factors. Please note also that this analysis is analogous to estimate the association using the Odds Ratios in a univariate logistic regression, with the inflation of the Odds Ratio as stated before. 6) To eliminate the effects of LPID co-administration on the occurrence of hypokalemia the authors restrict the analysis on 302 patients treated without LPIDs (In page 7 line 3). The adjusted Odds Ratios presented in figure 1 (a) have the same interpretation: Odds Ratios for the other risk factors are "adjusted" for co-treatment under the hypothesis that the effect is the same in the groups with and without LPIDs. The subgroup analysis would adjunct a new set of information if there is an interaction between risk factors and cotreatment. Have the authors tested the interaction between risk factors and co-treatment?
VERSION 1 -AUTHOR RESPONSE
Responses to the comments of Reviewer #1 1) According to the suggestions, Table showing Kampo-medicines containing licorice were newly prepared as the Table 2 in the revised version.
2) According to the suggestions, discussion part was divided into 3 subheads parts, Occurrence rate of hypokalemia in Kampo-medicines, Hypokalemia in pseudoaldosteronism, and Risk factors for YK preparations-induced hypokalemia.
Responses to the comments of Reviewer #2 ・P2 L20 , P6 L20:
Response: Although licorice contents for both YK and YKCH are equal (1.5g/day), the occurrence of hypokalemia in YK (26.6%) was unexpectedly high compared with YKCH (12.1%). This means that YK has a higher risk factor for hypokalemia compared with YKCH as reviewer's interpretation. This explanation was added in the results section (P6, L16-21) as easy to understand. A possible reason is the difference in GL contents between YK and YKCH as discussed in P10, L7-10.
・Fig1:
Response: According to the suggestion, risk candidates were analyzed by Cox proportional hazard model including univariate and multivariate analysis as shown in Table 4 of revised version instead of Figure. 1 in original version.
・Please write P-values in another column of Table2, 3.
Response: According to the suggestion, P-values were added in Table 3 of revised version (Table 2 in the original version). Table 3 in original version was deleted from the manuscript.
・P9 L8: ・P9 L13:
Response: Figure 2 was revised by using Kaplan-Meier method according to the other reviewer's suggestion. Patients treated with concomitant LPIDs showed a shorter time-to-occurence for hypokalemia than those without concomitant LIPDs as shown in Figure 2 . This result was statistically significant (p<0.001).
